Production of SARS-CoV-2 Virus-Like Particles in Insect Cells

Coronavirus disease (COVID-19) causes a serious threat to human health. Virus-like particles (VLPs) constitute a promising platform in SARS-CoV-2 vaccine development. In this study, the E, M, and S genes were cloned into multiple cloning sites of a new triple expression plasmid with one p10 promoter, two pPH promoters, and three multiple cloning sites. The plasmid was transformed into DH10 Bac(TM) Escherichia coli competent cells to obtain recombinant bacmid. Then the recombinant bacmid was transfected in ExpiSf9(TM) insect cells to generate recombinant baculovirus. After ExpiSf9(TM) cells infection with the recombinant baculovirus, the E, M, and S proteins were expressed in insect cells. Finally, SARS-CoV-2 VLPs were self-assembled in insect cells after infection. The morphology and the size of SARS-CoV-2 VLPs are similar to the native virions.

Automated summary

This study utilized virus-like particle technology to develop a SARS-CoV-2 vaccine, successfully expressing E, M, and S proteins in insect cells through gene cloning and cell transfection, ultimately achieving self-assembly of SARS-CoV-2 VLPs in insect cells.